Rituximab immunotherapy for ocular adnexal lymphoma: Clinicopathologic correlation with 5-year follow-up

Jason A. Sokol, Leon Landau, Simeon A. Lauer

Research output: Contribution to journalArticle

6 Scopus citations


Two patients with primary ocular adnexal mucosaassociated lymphoid tumor lymphoma were treated with rituximab immunotherapy. One patient had refused radiotherapy. The other had bilateral ischemic retinopathy, a relative contraindication to radiotherapy. Biopsies were performed 6 months after treatment. One patient had complete resolution of local disease, and the other had a partial response, remaining stable without signs of progression. During the 5 years of clinical follow-up, there was no evidence of systemic disease in either patient. Rituximab immunotherapy is an alternative to regional radiotherapy for ocular adnexal mucosa-associated lymphoid tumor lymphoma.

Original languageEnglish (US)
Pages (from-to)322-324
Number of pages3
JournalOphthalmic plastic and reconstructive surgery
Issue number4
Publication statusPublished - Jul 1 2009


ASJC Scopus subject areas

  • Surgery
  • Ophthalmology

Cite this